SAB Biotherapeutics: announces FDA Fast Track designation for SAB-142

What happened The filing says that on Oct 13, 2026, SAB Biotherapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new-onset Stage 3 type 1 diabetes (T1D).

Key details

• Announcement date: Oct 13, 2026.
• Product: SAB-142, described in the filing as a potentially disease-modifying immunotherapy for new-onset Stage 3 type 1 diabetes (T1D).
• Regulatory action: U.S. Food and Drug Administration granted Fast Track designation.
• The press release is filed as Exhibit 99.1 to the Current Report on Form 8-K; the report is signed by Samuel J. Reich, Chief Executive Officer, dated Oct 13, 2026.

Why it may matter This filing reports Item 8.01 (Other events), which covers events the company reports outside the other specified Form 8-K items, and includes an exhibit under Item 9.01. This filing does not show why the insider traded or why the company acted.